<DOC>
	<DOCNO>NCT00874536</DOCNO>
	<brief_summary>It assume 1/5 child diagnose attention-deficit-hyperactivity disorder ( ADHD ) treat . New treatment modality urgently need . Omega-3 fatty acid use setting , yet result conflict . The parent omega-3 fatty acid alpha-linolenic acid ( ALA ) use one trial . 40 child diagnose ADHD randomize consume either ALA placebo two month . Baseline end assessment include ADHD-related questionnaire computerize test . The investigator hypothesize ALA supplementation prove beneficial child ADHD .</brief_summary>
	<brief_title>Omega-3 Supplementation Attention-deficit-hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<criteria>ADHD diagnosis inform consent refusal test comorbidities medication supplement use</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>ADHD</keyword>
	<keyword>methylphenidate</keyword>
	<keyword>omega-3</keyword>
</DOC>